Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Keefe, Bruyette & Woods raised its price target on Horizon Bancorp to $21 from $19, endorsing an Outperform rating after the bank reported better-than-expected earnings. The bank’s higher pre-provision net revenue and net interest margin contributed to stronger top-line performance. Updated guidance and optimistic margin outlook prompted increased …
Keefe, Bruyette & Woods has increased its price objective for Banc of California to $23, citing robust growth metrics and return improvements that support the stock's valuation. The bank's latest earnings surpassed expectations, reinforcing confidence among analysts and prompting revisions to future earnings projections.
RBC Capital has increased the price target for Definium Therapeutics Inc to $36 from $20 and reaffirmed an Outperform rating. This adjustment is based on heightened expectations for the commercial success of Definium’s lead candidate, DT120, currently in late-stage trials for generalized anxiety disorder. The company’s market value stands near $1.6…
Keefe, Bruyette & Woods has increased its price target for Live Oak Bancshares to $146 from $132 and maintained an Outperform rating after the bank's fourth-quarter results exceeded analyst estimates. The bank showcased stronger-than-expected earnings and revenue growth while maintaining stable credit performance. However, KBW anticipates a reversa…
RBC Capital has increased its price target for Compass Pathways to $21, maintaining an Outperform rating amid advancing clinical developments and promising market insights from recent psychedelics symposiums. The company’s shares have shown notable gains over the past year, with excitement building ahead of upcoming trial data.
Shares of Nvidia experienced a notable increase following reports that Chinese regulatory bodies have given preliminary approval to major domestic technology firms to proceed with arrangements to acquire Nvidia's H200 AI chips. This marks a significant step toward resumption of AI chip imports into China, which had previously faced uncertainty. Whi…
Bank of America Global Research has pinpointed a focused list of European building materials companies poised for notable performance in 2026, highlighting key drivers such as earnings momentum, pricing power, and strong balance sheets. Amid a sector with limited valuation upside, select stocks demonstrate resilience connected to a housing market r…
Throughout 2025, Lista DAO transitioned from a liquid staking provider to the dominant Capital Routing Layer within the BNB ecosystem, achieving record market share and introducing significant new products including Smart Lending, a native Swap interface, and Fixed-Rate Borrowing. These developments enhance capital utilization, diversify product of…
Following Abbott Laboratories' release of its fourth-quarter earnings results, Oppenheimer has lowered its price target on the healthcare giant to $132 from $140 but retained its Outperform rating. The company's Q4 revenue and earnings per share fell short of estimates, influenced in part by underperformance in the Nutrition segment. Despite a rece…
The United Nations High Commissioner for Human Rights, Volker Turk, has publicly urged the United States government to align its immigration enforcement practices with international human rights standards. Highlighting reports of arbitrary detentions and excessive force by federal immigration agents, Turk emphasized the necessity for due process an…
TD Cowen has lowered its price target for McCormick & Company to $75 from $82, following the company's fourth-quarter earnings miss and subdued fiscal 2026 guidance. Higher input costs and accelerated ERP spending contributed to these challenges, leading to tempered growth expectations. Despite these headwinds, the firm retains its Buy rating, citi…
Evercore ISI has reduced its price objective for CSX to $40 from $41 while keeping an Outperform rating on the company's stock. The adjustment follows CSX's fourth-quarter 2025 earnings report, which revealed earnings per share below estimates and volumes and yields underperforming across segments. Despite these challenges, the company forecasts mo…
BTIG has boosted its price target for FTAI Aviation to $335 from $230, maintaining a Buy rating after the company announced a multi-year partnership with CFM International for component and repair support on CFM56 engines. This agreement reinforces FTAI's business trajectory and alleviates concerns about OEM relations. Shares have surged notably ov…
TD Cowen has maintained its Buy rating on Check Point Software stock, setting a $285 price target that suggests considerable market upside. The firm highlights ongoing demand from firewall updates and rapid uptake of Harmony Email and SASE solutions as drivers for the company's positive near-term momentum. Additional analyst endorsements and recent…
Kepler Cheuvreux upgraded its outlook on ProSiebenSat.1 to 'hold' from 'reduce' as the broadcaster’s stock price stabilized near its fundamental worth amid persistent market challenges and structural headwinds in the German TV advertising market. The upgrade follows a period of underperformance linked to the change in ownership and management under…
Martin Kocher, the president of the Austrian central bank, has urged the European Central Bank (ECB) to exercise caution before implementing policy changes in response to ongoing uncertainties. Speaking to German media, Kocher highlighted the need to avoid premature commitments that could complicate future communications, especially when inflation …
Kepler Cheuvreux analyst Richard Withagen has downgraded Coca-Cola HBC's stock from Hold to Reduce, citing potential near-term value destruction due to its pending $3.4 billion acquisition of Coca-Cola Beverages Africa (CCBA). The acquisition introduces execution risk and may dilute profitability, with the enlarged group’s returns likely to be weig…
Austrian central bank governor Martin Kocher has emphasized a measured approach for the European Central Bank (ECB) when considering policy adjustments in response to heightened geopolitical tensions. Speaking in an interview with a German media outlet, Kocher highlighted the risks of premature moves absent clear inflationary direction, stressing t…
Wells Fargo has adjusted its price target for Mosaic (NYSE:MOS) downward to $27 from $28, maintaining an Equal Weight rating. The revision reflects diminished fourth-quarter expectations tied to weaker conditions in the Brazilian market and SSP production cutbacks. Mosaic’s Q4 and full-year 2025 earnings estimates have also been trimmed. Concurrent…
Wells Fargo has increased its price target for Procter & Gamble (NYSE:PG) to $165, up from $158, while reiterating an Overweight rating following the company's fiscal second-quarter earnings. Despite the results meeting modest expectations, the firm points to solid international operations and the possibility of an improved U.S. market as factors t…
Wells Fargo has increased its price target for Clorox to $115 from $108 after the company announced its acquisition of GOJO Industries, producer of Purell hand sanitizer, for $2.25 billion in cash. The move is viewed as a strategic effort to enhance Clorox's product portfolio and growth prospects. The acquisition is expected to be neutral to earnin…
Shares of SLM Corp rose in after-market trading after Wells Fargo increased its price target to $32.00 from $30.00, maintaining an Overweight rating on the student lending firm. The move follows the release of fourth-quarter earnings that exceeded estimates and an outlook signaling robust growth in earnings per share through 2027. Despite some metr…
Wells Fargo has trimmed its price objective for Abbott Laboratories to $122 from $146 while reiterating an Overweight rating. The revision follows Abbott's fourth-quarter earnings release showing a revenue shortfall attributed primarily to the Nutrition segment alongside other temporary setbacks. Despite these challenges, the company’s earnings per…
Wells Fargo has adjusted its price target on RLI Corp to $59 from $62, maintaining an Equal Weight rating despite the company's slower-than-expected revenue growth. The insurer prioritizes profitability over expansion, holding a robust 24% return on equity and consistent dividends, even as property market challenges temper revenue forecasts for 202…
Recent developments surrounding U.S. interest in Greenland have sparked significant market reactions and highlighted persistent uncertainties in international trade and monetary policies. Following intense speculation and shifts in diplomatic stances, markets experienced notable volatility, revealing sector vulnerabilities and geopolitical concerns…
